Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Tennessee for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Tennessee only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Tennessee (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mark Womack (NPI 1689887788)

Field	Value
Entity Type	Individual
Organization	Mark Womack
Address	605 Glenwood Drive
City	Chattanooga
State	TN
ZIP	37404
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 7, 2007

Payer Source	Total Paid
Medicare	$2.4M
Medicaid	$0

Key Findings

This provider’s public billing footprint is effectively single‑payer: lifetime Medicare revenue is $2.4M while there is no Medicaid billing on file, and the top three Medicare codes account for 79.0% of the provider’s Medicare revenue. That concentration and absence of Medicaid activity indicate the practice’s commercial scale is driven almost entirely by Medicare patients and Medicare‑reimbursed drug/infusion services.

The code mix is consistent with an on‑site oncology infusion practice: two high‑revenue biologic drug codes, J9271 and J9144, dominate the portfolio alongside chemotherapy administration codes such as 96413, 96365 and G0498. These items reflect recurrent in‑office administration of monoclonal antibodies and systemic cancer therapies rather than primarily procedure‑based or procedural subspecialty work.

Revenue concentration is heavily focused on single‑drug reimbursements: J9271 (injection, pembrolizumab) is listed with $903K revenue (38.0% of Medicare revenue) and J9144 (injection, daratumumab) with $868.3K revenue (36.5% of Medicare revenue), while the top three codes together are reported to account for 79.0% of Medicare revenue. This pattern shows that a very small set of drug codes drives the large majority of the provider’s Medicare receipts.

Competitive standing varies by drug: for daratumumab (J9144) the provider ranks #32 of 615 nationally (94th percentile; notably above typical national volume), signaling above‑typical national throughput for that therapy, while for pembrolizumab (J9271) the provider ranks #346 of 1841 (81th percentile; typical, unremarkable volume) and appears to be a more modest participant relative to national peers for that particular drug. In short, the provider is a high‑volume daratumumab administrator nationally but only a typical pembrolizumab administrator.

Evaluation/management coding shows unusually high intensity of office visits: 99215 appears with 533 claims and $67.2K revenue and is flagged as an "extreme outlier" at the 99th percentile, while 99214 (747 claims, $61.3K) is at the 95th percentile and described as "notably above typical." These E/M patterns are consistent with frequent, high‑complexity patient encounters and ongoing management of medically complex oncology patients.

The practice also shows high engagement with oncology‑specific program payments and supportive care lines: M0010 (EOM monthly enhanced oncology services) appears with 323 claims, $23.3K revenue and ranks #13 of 544 (98th percentile; notably above typical), and J1454 (fosnetupitant + palonosetron) ranks #19 of 422 (95th percentile; notably above typical) with $49.8K revenue. Together these items suggest active participation in enhanced oncology care services and systematic use of antiemetic regimens tied to infusion therapy.

Routine laboratory and monitoring activity supports the infusion/oncology profile: codes such as 80053 (1.7K claims, $17K; 97th percentile), 85025 (2.3K claims, $16.2K; 98th percentile), and 36415 (1.8K claims, $14.6K; 99th percentile) appear with high claim counts and high relative percentiles. The volume of these lower‑reimbursed but high‑frequency services is consistent with frequent in‑clinic monitoring required for systemic cancer therapy.

The provider’s NPI was enumerated on 2007‑05‑07 (about ~19 years ago), indicating an established clinical presence. Combined with the concentrated drug revenue profile, high E/M intensity, and strong ranking on select oncology model and drug codes, the data portray a longstanding hematology/oncology practice in Chattanooga that is operationally centered on Medicare‑reimbursed infusion oncology services.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

75 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	21,000	$40	$903K
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	24,120	$40	$868.3K
J0897	Injection, denosumab, 1 mg	5,580	$20	$106K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	530	$130	$67.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	750	$80	$61.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	27,000	$1	$54K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	150	$330	$49.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	510	$90	$45.5K
J1439	Injection, ferric carboxymaltose, 1 mg	39,000	$1	$39K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	320	$90	$27.5K

Showing 1–10 of 75

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 75 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Tennessee Distribution

Mark Womack — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Tennessee

Full comparison — all codes billed, vs. state median

75 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	16	50	17,400	$40	$776.1K
J9144	2	20	10,080	$40	$466.3K
J0897	63	240	2,940	$20	$85K
J0881	24	70	19,050	$1	$54.4K
J2506	34	40	430	$80	$46.7K
J1439	43	90	34,130	$1	$38.6K
J1454	5	70	70	$340	$25.6K
J9217	78	110	130	$130	$22K
96413	26	240	150	$90	$18.9K
99214	520	11,370	120	$80	$16.6K

Showing 1–10 of 75

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mark Womack, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tennessee Oncology PLLC	TN	Hematology & Oncology Physician	$0	$8.5M
James Gray	TN	Radiation Oncology Physician	$4.9M	$0
Bertrand Anz	TN	Hematology & Oncology Physician	$2.4M	$0
Dana Thompson	TN	Medical Oncology Physician	$2.2M	$0
Kent Shih	TN	Hematology & Oncology Physician	$2.2M	$0
Joshua Mondschein	TN	Radiation Oncology Physician	$2.1M	$0
Derek Holland	TN	Hematology & Oncology Physician	$2M	$0
Josiah Magnusson	FL	Nuclear Medicine Physician	$1.8M	$0
William Donnellan	TN	Hematology & Oncology Physician	$1.7M	$0
Clint Kingsley	AL	Hematology & Oncology Physician	$1.6M	$22K

Nearby Providers

Other providers in the same ZIP code as Mark Womack, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Parkridge Medical Center, Inc.	TN	General Acute Care Hospital	$0	$26.8M
County Of Hamilton	TN	Land Ambulance	$3.2M	$10.4M
Orange Grove Center, Inc.	TN	Developmentally Disabled Services Day Training Agency	$0	$7.8M
Memorial Health Care System Inc.	TN	General Acute Care Hospital	$0	$4.1M
Erlanger Behavioral Health, LLC	TN	Psychiatric Hospital	$0	$2.2M
Gregory Sutton	TN	Hematology & Oncology Physician	$1.6M	$0
Edward Arrowsmith	TN	Hematology & Oncology Physician	$1.4M	$0
Benjamin Nadeau	TN	Hematology & Oncology Physician	$1.3M	$0
Doloris Hawk	TN	Family Nurse Practitioner	$1.1M	$0
Davey Daniel	TN	Hematology & Oncology Physician	$870.3K	$0

Mark Womack — Billing Profile & Reimbursement Data

Sign up for Mark Womack — Billing Profile & Reimbursement Data policy alerts

Mark Womack — Billing Profile & Reimbursement Data

Sign up for Mark Womack — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References